StockData
BDPTOTCPharmaceutical PreparationsFiscal year ends December 31

BIOADAPTIVES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00−0.00 (-5.56%)

Close on Oct 19, 2026

Market cap
$478.03K
P/E (TTM)
–
Dividend yield
–

About Bioadaptives

Pharmaceutical Preparations, SIC 2834

BioAdaptives, Inc. researches, develops, markets, and distributes natural nutraceutical products and medical devices designed to support human and animal health. Its portfolio features plant-, fungal-, and algal-based dietary supplements targeting cognitive enhancement, regenerative wellness, and weight management, with brand offerings including MyndMed, Xcellara, Zeranovia, Wynovia, and PawPa Regen canine chews. The company also distributes the Lung Flute, an FDA-cleared respiratory medical device. BioAdaptives serves consumers directly through digital marketing channels and reaches patients via partnerships with telehealth platforms, medical communities, pharmacies, athletic clubs, and senior living communities.

The company operates primarily within the United States while pursuing international expansion for its respiratory device line, sourcing raw ingredients worldwide from sustainable agricultural suppliers. BioAdaptives conducts business through outsourced manufacturing and research partners, maintaining a single corporate office location. The company maintains its corporate headquarters at a single facility located in Las Vegas, Nevada.

Summary of the business section of Bioadaptives's latest annual report, written by StockData.

Company profile

Company

Legal name
BIOADAPTIVES, INC.
Founded
2013
Headquarters
Las Vegas, NV
Address
2620 Regatta Drive, Suite 102 89128
Phone
(702) 659-8829
Employees
1, Dec 31, 2015
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BOLADALE LAWAL & CO., Lagos, Nigeria

Stock & identifiers

Ticker
BDPT
Exchange
OTC
IPO date
Jul 9, 2014
Shares outstanding
197M, Aug 13, 2026
Public float
$252.18K, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
2-for-1, Jan 23, 2025; 1-for-300 reverse, Nov 21, 2024
SEC CIK
1575142
EIN
46-2592228

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark P. FrissoraDirector–
Gimhana Sasanka DissanayakeDirector125,000

Employees

Headcount reported in annual reports

“As of April 14, 2016, the Company had 1 full-time employee and no part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 14, 2026Late filingNotification of late filing
Mar 31, 2026Late filingNotification of late filing
Mar 31, 2025Late filingNotification of late filing
Nov 14, 2024Late filingNotification of late filing
Aug 15, 2024Late filingNotification of late filing
May 15, 2024Late filingNotification of late filing
May 14, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 1, 2024Late filingNotification of late filing
Mar 31, 2017DeregistrationTermination of SEC registration (Form 15)
Nov 15, 2016Late filingNotification of late filing
Aug 16, 2016Late filingNotification of late filing
May 17, 2016Late filingNotification of late filing
Mar 31, 2016Late filingNotification of late filing
Nov 16, 2015Late filingNotification of late filing
Aug 14, 2015Late filingNotification of late filing
May 18, 2015Late filingNotification of late filing
Apr 23, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 31, 2015Late filingNotification of late filing
May 23, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
May 15, 2014Late filingNotification of late filing
Mar 28, 2014Late filingNotification of late filing
Oct 25, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 19, 2013Name changeName changed from APEX 8 Inc. to BIOADAPTIVES, INC.